Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Chief Scientific Officer | December 15, 2017 | December 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date December 15, 2017 · Filed December 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 50,460 |
Reported balance
After 2017-12-15 transaction · row 1
1 source rowRow 1 · 2017-12-15 · Grant · Acquired 809 · Balance 50,460 |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectBy Trust | 300,164 |
Reported balance
Holding disclosure · report date 2017-12-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,164 F1: These shares are held by the Herman Trust, dated March 16, 2001, of which Reporting Person is a co trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held by the Herman Trust, dated March 16, 2001, of which Reporting Person is a co trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2017 Filed Dec 19, 2017 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock, $0.0001 par value | 809 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-029155 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,460 Read SEC document |
| August 08, 2017 Filed Aug 10, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 17,535 | $15.02 | $263,300.30 |
DisclosureSEC source: 0000899243-17-020046 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,651 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $15.00 to $15.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 600 | $15.00 | $9,000.00 |
DisclosureSEC source: 0000899243-17-018067 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,186 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 1,732 | $20.98 | $36,342.04 |
DisclosureSEC source: 0000899243-17-015285 · doc4.xml · nonDerivative · entry 2 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,786 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $20.90 to $21.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 9,601 | $20.20 | $193,949.80 |
DisclosureSEC source: 0000899243-17-015285 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,518 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $19.85 to $20.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 01, 2017 Filed May 3, 2017 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 11,333 | $20.00 | $226,626.00 |
DisclosureSEC source: 0000899243-17-011610 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,119 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $19.25 to $20.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 03, 2017 Filed Apr 5, 2017 20:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 11,333 | $20.73 | $234,985.22 |
DisclosureSEC source: 0000899243-17-009488 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,452 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $20.45 to $21.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 11,333 | $24.19 | $274,171.34 |
DisclosureSEC source: 0000899243-17-006341 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,785 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $23.85 to $24.625, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 11,333 | $27.37 | $310,154.74 |
DisclosureSEC source: 0000899243-17-002713 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,118 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $26.95 to $27.95, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 683 | $28.60 | $19,536.33 |
DisclosureSEC source: 0000899243-17-000442 · doc4.xml · nonDerivative · entry 2 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,451 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $28.525 to $28.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 10,650 | $27.90 | $297,186.12 |
DisclosureSEC source: 0000899243-17-000442 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,134 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.50 to $28.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 01, 2016 Filed Dec 6, 2016 00:00 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 8,133 | $27.55 | $224,077.98 |
DisclosureSEC source: 0001140361-16-088854 · doc1.xml · nonDerivative · entry 2 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,784 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $27.45 to $27.80 inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.s Read SEC document |
| December 01, 2016 Filed Dec 6, 2016 00:00 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,200 | $27.01 | $86,445.12 |
DisclosureSEC source: 0001140361-16-088854 · doc1.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,917 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $26.40 to $27.35 inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.s Read SEC document |
| November 01, 2016 Filed Nov 3, 2016 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 11,333 | $27.53 | $312,041.69 |
DisclosureSEC source: 0000899243-16-032715 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,117 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $27.00 to $27.95, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 3,237 | $26.26 | $84,997.79 |
DisclosureSEC source: 0000899243-16-031223 · doc4.xml · nonDerivative · entry 2 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,450 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $26.02 to $26.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 03, 2016 Filed Oct 5, 2016 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 8,096 | $25.47 | $206,203.50 |
DisclosureSEC source: 0000899243-16-031223 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,687 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.02 to $26.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:05 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | SaleCommon Stock, $0.0001 par value | 16,999 | $29.99 | $509,715.02 |
DisclosureSEC source: 0000899243-16-028532 · doc4.xml · nonDerivative · entry 1 Herman Alan C. · CIK 0001622080 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,783 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.5450 to $30.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.